Clene Nanomedicine Presents Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021

    NEXT STORY
    Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos
    PREV STORY
    Novan Reports Full Year 2020 Financial Results and Provides Corporate Update
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    ADMA Biologics Enters Into $100 Million Credit Facility Loan Amendment with Perceptive Advisors

    author_avatar
    NASDAQ Market News

    Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operational Progress

    author_avatar
    NASDAQ Market News

    Allena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming ASN Kidney Week and ACR/ARP Annual Meeting

    author_avatar
    NASDAQ Market News